1+ hour, 55+ min ago  (787+ words) The FDA has approved Trodelvy (sacituzumab govitecan-hziy) for first-line treatment of metastatic triple-negative breast cancer as both a monotherapy and in combination with pembrolizumab, supported by Phase 3 data from the ASCENT-03 and ASCENT-04 trials. The FDA has approved Gilead's Trodelvy…...